Capricor Therapeutics, Inc.

Home
United States
San Diego, CA
Capricor Therapeutics, Inc.

Capricor ( ) is a biotechnology company developing transformative therapeutics for diseases.

Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions.

01/20/2026

We are pleased to provide a regulatory update on Deramiocel following FDA review of the HOPE-3 topline data. The FDA has requested the HOPE-3 clinical study report, an expected step as the BLA review progresses.
Click to read the release: https://bit.ly/4b8MiWU

01/14/2026

Our CEO, Linda Marbán, joined Amy Brown on at the JPM Healthcare Conference to reflect on a meaningful year for our Duchenne muscular dystrophy program. The conversation highlights key milestones for Deramiocel, including the Phase 3 HOPE-3 readout as well as next steps in the regulatory review and what this progress could mean for individuals and families in the DMD community.

Watch the full interview here: https://www.biotechtv.com/post/capricor-january-13-2026

12/18/2025

In case you missed it: Parent Project Muscular Dystrophy and Capricor hosted a community webinar discussing positive topline results from the Phase 3 HOPE-3 trial evaluating Deramiocel in Duchenne muscular dystrophy, including a review of the data and how the findings inform ongoing regulatory discussions and next steps with the FDA.
Catch the webinar replay here: https://bit.ly/4p6zt2L

12/17/2025

Today at 1:00 p.m. ET

Join and Capricor for a community webinar discussing positive topline results from the Phase 3 HOPE-3 trial evaluating Deramiocel in DMD. We’ll review the data and discuss how the findings inform ongoing regulatory discussions, including next steps with the FDA.

Read the press release: https://bit.ly/3KWo3jY

Register here: https://bit.ly/3KMGNCt

12/16/2025

Today marks a defining moment for the Duchenne community. The U.S. Department of Health and Human Services has added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, expanding newborn screening nationwide—an important step toward earlier diagnosis and improved outcomes for families.
We are proud to stand alongside the community as this progress continues.

12/11/2025

Capricor is pleased to be participating today in the Oppenheimer Movers in Rare Disease Summit in New York. We will be featured on a rare disease panel and participating in a series of one-on-one meetings to discuss our recent progress and the path ahead.

12/04/2025

Thank you to everyone who joined our conference call and webcast yesterday to review the positive topline results from our pivotal Phase 3 HOPE-3 study of Deramiocel. Interest in the event was exceptionally high, and due to the unusually heavy traffic, our webcast platform experienced intermittent delays that may have prevented some viewers from accessing the full live stream.
The full replay and presentation slides are now available on our website here. https://bit.ly/4pObKor

12/03/2025

Following this morning’s announcement of positive topline results from our pivotal Phase 3 HOPE-3 clinical study, Capricor will be presenting today at the Piper Sandler 37th Annual Healthcare Conference. We will be featured in a fireside chat starting at 11:30 a.m. ET.
To access the live webcast, click here https://bit.ly/49Pz3d3

12/03/2025

Breaking: Capricor is extremely pleased to announce positive topline results from our pivotal Phase 3 HOPE-3 clinical study evaluating Deramiocel in Duchenne muscular dystrophy.
HOPE-3 met its primary endpoint and key cardiac secondary endpoint, with all Type 1 error–controlled secondary endpoints also achieving statistical significance. Deramiocel maintained a favorable safety and tolerability profile consistent with prior studies.
We are grateful to the patients, families, investigators and partners who made this milestone possible.
Read the full announcement: https://bit.ly/3Ko9KV6
Join our conference call and webcast today at 8:00 a.m. ET. https://bit.ly/48O3SOb

11/11/2025

In case you missed it: Capricor shared third-quarter 2025 financial results and a corporate update highlighting continued progress across our programs.
Catch the replay of our webcast here: https://bit.ly/4nqoZtX

11/11/2025

On Veterans Day, we pause to honor the courage, sacrifice and service of our nation’s veterans, and the families who stand beside them. Your commitment inspires us to pursue life-changing science with purpose every day.
Thank you for your service.

11/10/2025

We just released our third quarter 2025 financial results and provided a corporate update. Click here to read the release: https://bit.ly/43X4fD9

Address

10865 Road To The Cure
San Diego, CA
92121

Website

http://capricor.com/

Alerts

Be the first to know and let us send you an email when Capricor Therapeutics, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Capricor Therapeutics, Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in San Diego?

01/20/2026

01/14/2026

12/18/2025

12/17/2025

12/16/2025

12/11/2025

12/04/2025

12/03/2025

12/03/2025

11/11/2025

11/11/2025

11/10/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share